A

ACELYRIN Inc
NASDAQ:SLRN

Watchlist Manager
ACELYRIN Inc
NASDAQ:SLRN
Watchlist
Price: 4.29 USD 0.94% Market Closed
Market Cap: 430.4m USD
Have any thoughts about
ACELYRIN Inc?
Write Note

Relative Value

There is not enough data to reliably calculate the relative value of SLRN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SLRN Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.1
Industry
22.8
Forward
-1.6
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-4.3
Industry
22.6
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.2
Industry
23.7
vs History
70
vs Industry
68
Median 3Y
1
Median 5Y
1
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
vs History
25
vs Industry
16
Median 3Y
0
Median 5Y
0
Industry
4.6
Forward
0.4
vs History
25
vs Industry
14
Median 3Y
0
Median 5Y
0
Industry
4.3
Forward
0.4
vs History
25
vs Industry
17
Median 3Y
0
Median 5Y
0
Industry
6.5
vs History
25
vs Industry
13
Median 3Y
0
Median 5Y
0
Industry
4.2
vs History
vs Industry
18
Median 3Y
-1.4
Median 5Y
-1.4
Industry
4.8

Multiples Across Competitors

SLRN Competitors Multiples
ACELYRIN Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
ACELYRIN Inc
NASDAQ:SLRN
428.8m USD 0 -1.6 0.4 0.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 599 188.7 -178 703.4 -217 002.8 -214 526.5
US
Abbvie Inc
NYSE:ABBV
314.1B USD 5.7 61.8 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
149.2B USD 4.6 35.3 16.7 31.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.2B USD 11.5 -254.6 25.4 26.7
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 4 903.3 10 10
US
Epizyme Inc
F:EPE
94.1B EUR 1 873.7 -478.1 -520.7 -506.8
AU
CSL Ltd
ASX:CSL
135.2B AUD 5.9 33 20.4 25.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88B USD 6.4 18.9 17.3 19.3
US
Seagen Inc
F:SGT
39.3B EUR 18 -55.3 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
35B EUR 19 -133.3 -107.5 -78.4
P/E Multiple
Earnings Growth
US
A
ACELYRIN Inc
NASDAQ:SLRN
Average P/E: 210.4
Negative Multiple: -1.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 703.4 N/A
US
Abbvie Inc
NYSE:ABBV
61.8
412%
US
Amgen Inc
NASDAQ:AMGN
35.3
74%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -254.6
48%
US
Gilead Sciences Inc
NASDAQ:GILD
903.3
77%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.1 N/A
AU
CSL Ltd
ASX:CSL
33
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -133.3 N/A
EV/EBITDA Multiple
EBITDA Growth
US
A
ACELYRIN Inc
NASDAQ:SLRN
Average EV/EBITDA: 15.1
0.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 002.8 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
29%
US
Amgen Inc
NASDAQ:AMGN
16.7
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
43%
US
Gilead Sciences Inc
NASDAQ:GILD
10
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.7 N/A
AU
CSL Ltd
ASX:CSL
20.4
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.5 N/A
EV/EBIT Multiple
EBIT Growth
US
A
ACELYRIN Inc
NASDAQ:SLRN
Average EV/EBIT: 19.6
0.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 526.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
90%
US
Amgen Inc
NASDAQ:AMGN
31.6
90%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
45%
US
Gilead Sciences Inc
NASDAQ:GILD
10
32%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -506.8 N/A
AU
CSL Ltd
ASX:CSL
25.4
54%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
42%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -78.4 N/A

See Also

Discover More
Back to Top